Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,101 to 1,120 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer. | Sci Rep | 2023 | 37316561 | PubTator, text mining | PubMed |
| Targeting triple-negative breast cancer: A clinical perspective. | Oncol Res | 2023 | 37305385 | PubTator, text mining | PubMed |
| Patient-Induced Pluripotent Stem Cell-Derived Hepatostellate Organoids Establish a Basis for Liver Pathologies in Telomeropathies. | Cell Mol Gastroenterol Hepatol | 2023 | 37302654 | PubTator, text mining | PubMed |
| Mechanisms of Resistance to Antibody-Drug Conjugates. | Int J Mol Sci | 2023 | 37298631 | PubTator, text mining | PubMed |
| Precision Medicine to Treat Urothelial Carcinoma-The Way Forward. | Cancers (Basel) | 2023 | 37296985 | PubTator, text mining | PubMed |
| Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer. | Cancers (Basel) | 2023 | 37296893 | PubTator, text mining | PubMed |
| The Role of Artificial Intelligence in the Detection and Implementation of Biomarkers for Hepatocellular Carcinoma: Outlook and Opportunities. | Cancers (Basel) | 2023 | 37296890 | PubTator, text mining | PubMed |
| The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data. | Cell Biosci | 2023 | 37291676 | PubTator, text mining | PubMed |
| Cancer immune exclusion: breaking the barricade for a successful immunotherapy. | Front Oncol | 2023 | 37284199 | PubTator, text mining | PubMed |
| Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. | Jpn J Clin Oncol | 2023 | 37279591 | PubTator, text mining | PubMed |
| Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast. | Oncol Ther | 2023 | 37278969 | PubTator, text mining | PubMed |
| Polypharmacology: promises and new drugs in 2022. | Pharmacol Rep | 2023 | 37278927 | PubTator, text mining | PubMed |
| TROP2 translation mediated by dual m6A/m7G RNA modifications promotes bladder cancer development. | Cancer Lett | 2023 | 37268280 | PubTator, text mining | PubMed |
| Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation. | Front Oncol | 2023 | 37265791 | PubTator, text mining | PubMed |
| The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases. | Ann Med | 2023 | 37260331 | PubTator, text mining | PubMed |
| PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer. | Pharmaceuticals (Basel) | 2023 | 37259457 | PubTator, text mining | PubMed |
| Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. | Front Oncol | 2023 | 37251935 | PubTator, text mining | PubMed |
| Precision Medicine in Bladder Cancer: Present Challenges and Future Directions. | J Pers Med | 2023 | 37240925 | PubTator, text mining | PubMed |
| Rapid Generation of Pulmonary Organoids from Induced Pluripotent Stem Cells by Co-Culturing Endodermal and Mesodermal Progenitors for Pulmonary Disease Modelling. | Biomedicines | 2023 | 37239147 | PubTator, text mining | PubMed |
| Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer. | Biology (Basel) | 2023 | 37237509 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=56